Metz Tumor Progress Express (Issue 007)

：，。。enjoy～

：，。。enjoy～：，。。enjoy～

：（006）

（006）（006）（006）

1.

1.

Previous studies have shown that radical radiotherapy or radiotherapy and chemotherapy (RT/CRT) of head and neck squamous cell carcinoma (HNSCC) is associated with a large number of toxicity.

In this population-based study, the researchers aimed to study the early risk factors, microbial etiology, prognosis of bloodborne infections (BSI) after RT/CRT and their impact on early non-cancer mortality.

Researchers included 5674 patient information and observed 238 BSI events.

The results of this study show that the risk of BSI is related to several factors related to patients and diseases.

Reference for details: Reference for details: Reference for details: Reference fordetails:Br J Cancer: Analysis of blood infection in patients with head and neck cancer after radical radiotherapy

2.

2.

Concurrent radiotherapy and chemotherapy is the standard treatment for unresectable locally advanced squamous cell carcinoma of the head and neck.

The results of this study showed that in high-risk locally advanced head and neck squamous cell carcinoma patients, adding avelumab to concurrent chemoradiation did not improve the progression-free survival of patients.

In high-risk patients with locally advanced head and neck squamous cell carcinoma, adding avelumab to concurrent chemoradiation did not improve the patient’s progression-free survival.

For more information: Lancet Oncology: Avelumab combined with concurrent chemoradiation and chemotherapy for locally advanced head and neck squamous cell carcinoma: a randomized, double-blind, placebo-controlled, multi-center, phase 3 trial.

3.

Globally, breast cancer is one of the most common cancers in women.

The treatment of ESBC includes paclitaxel chemotherapy, which is a treatment strategy closely related to peripheral neuropathy (PN).

The prevalence of persistent peripheral neuropathy (PN) in ESBC surviving patients is currently unclear.

The results of the study revealed that compared with normal women, PN is more common in ESBC survivors, and many symptoms persist over time.
Therefore, relevant risk factors should be considered when formulating treatment strategies for patients.
The results of the study revealed that compared with normal women, PN is more common in ESBC survivors, and many symptoms persist over time.
Therefore, relevant risk factors should be considered when formulating treatment strategies for patients.
The results of the study revealed that compared with normal women, PN is more common in ESBC survivors, and many symptoms persist over time.
Therefore, relevant risk factors should be considered when formulating treatment strategies for patients.
The results of the study revealed thatcompared with normal women, PN is more common in ESBC survivors, and many symptoms persist over time.
Therefore, relevant risk factors should be considered when formulating treatment strategies for patients.
The results of the study revealed thatcompared with normal women, PN is more common in ESBC survivors, and many symptoms persist over time.
Therefore, relevant risk factors should be considered when formulating treatment strategies for patients.
Compared with normal women, PN is more common in ESBC survivors, and many symptoms persist over time.
Therefore, relevant risk factors should be considered when formulating treatment strategies for patients.

For details, please refer to: Br J Cancer: Cohort Study of Persistent Neuropathy in Early Breast Cancer Survivors

Reference for details: Reference fordetails:Reference for details: Reference for details:Reference fordetails:Br J Cancer: Cohort study of persistent neuropathy among early breast cancer survivors

4.
J Gastroenterology H: Levatinib can reduce the risk of disease progression in patients with advanced hepatocellular carcinoma

4.
J Gastroenterology H: Lovatinib can reduce the risk of disease progression in patients with advanced hepatocellular carcinoma 4.
J Gastroenterology H: Lovatinib can reduce the risk of disease progression in patients with advanced hepatocellular carcinoma 4.
J Gastroenterology H: Lovatinib Can reduce the risk of disease progression in patients with advanced hepatocellular carcinoma4.
J Gastroenterology H: Levatinib can reduce the risk of disease progression in patients with advanced hepatocellular carcinoma

Recently, a new drug for the treatment of HCC, lenvatinib , was approved by the US FDA for clinical treatment.
A number of studies have also compared the prognosis of patients with unresectable HCC treated with sorafenib and lenvatinib.
This study aimed to explore the treatment outcome and safety of lenvatinib compared with sorafenib, and to identify independent predictors of adverse outcomes.

Recently, a new drug for the treatment of HCC, lenvatinib , was approved by the US FDA for clinical treatment.
A number of studies have also compared the prognosis of patients with unresectable HCC treated with sorafenib and lenvatinib.
This study aimed to explore the treatment outcome and safety of lenvatinib compared with sorafenib, and to identify independent predictors of adverse outcomes.
Recently, a new drug for the treatment of HCC, lenvatinib , was approved by the US FDA for clinical treatment.
A number of studies have also compared the prognosis of patients with unresectable HCC treated with sorafenib and lenvatinib.
This study aimed to explore the treatment outcome and safety of lenvatinib compared with sorafenib, and to identify independent predictors of adverse outcomes.
Recently, a new drug for the treatment of HCC, lenvatinib, was approved bythe USFDAfor clinical treatment.
A number of studies have also compared the prognosis of patients with unresectable HCC treated with sorafenib and lenvatinib.
This study aimed to explore the treatment outcome and safety of lenvatinib compared with sorafenib, and to identify independent predictors of adverse outcomes.
Recently, a new drug for the treatment of HCC, lenvatinib, was approved bythe USFDAfor clinical treatment.
A number of studies have also compared the prognosis of patients with unresectable HCC treated with sorafenib and lenvatinib.
This study aimed to explore the treatment outcome and safety of lenvatinib compared with sorafenib, and to identify independent predictors of adverse outcomes.

Researchers collected clinical data of patients with advanced HCC who were treated with lenvatinib or sorafenib at the Liver Disease Center of Yonsei University School of Medicine in South Korea from October 2018 to October 2019.

Researchers collected clinical data of patients with advanced HCC who were treated with lenvatinib or sorafenib at the Liver Disease Center of Yonsei University School of Medicine in South Korea from October 2018 to October 2019.
Researchers collected clinical data of patients with advanced HCC who were treated with lenvatinib or sorafenib at the Liver Disease Center of Yonsei University School of Medicine in South Korea from October 2018 to October 2019.
Researchers collected clinical data of patients with advanced HCC who were treated with lenvatinib or sorafenib at the Liver Disease Center of Yonsei University School of Medicine in South Korea from October 2018 to October 2019.
Researchers collected clinical data of patients with advanced HCC who were treated with lenvatinib or sorafenib at the Liver Disease Center of Yonsei University School of Medicine in South Korea from October 2018 to October 2019.

The results of the study revealed that lenvatinib-treated patients showed a longer disease progression-free survival time than sorafenib-treated patients.
In addition, there was no significant difference in mortality between the two groups, which indicates that levatinib is not inferior to sorafenib in terms of lifespan extension.

The results of the study revealed that lenvatinib-treated patients showed a longer disease progression-free survival time than sorafenib-treated patients.
In addition, there was no significant difference in mortality between the two groups, which indicates that levatinib is not inferior to sorafenib in terms of lifespan extension.
The results of the study revealed that lenvatinib-treated patients showed a longer disease progression-free survival time than sorafenib-treated patients.
In addition, there was no significant difference in mortality between the two groups, which indicates that levatinib is not inferior to sorafenib in terms of lifespan extension.
The results of the study revealed that lenvatinib-treated patients showed a longer disease progression-free survival time than sorafenib-treated patients.
In addition, there was no significant difference in mortality between the two groups, which indicates that levatinib is not inferior to sorafenib in terms of lifespan extension.
The results of the study revealed that lenvatinib-treated patients showed a longer disease progression-free survival time than sorafenib-treated patients.
In addition, there was no significant difference in mortality between the two groups, which indicates that levatinib is not inferior to sorafenib in terms of lifespan extension.
Patients treated with lenvatinib showed that patients treated with bisorafenib had longer disease progression-free survival.
In addition, there was no significant difference in mortality between the two groups, which indicates that levatinib is not inferior to sorafenib in terms of lifespan extension.
Patients treated with lenvatinib showed that patients treated with bisorafenib had longer disease progression-free survival.
In addition, there was no significant difference in mortality between the two groups, which indicates that levatinib is not inferior to sorafenib in terms of lifespan extension.

For details, please refer to: J Gastroenterology H: Levatinib can reduce the risk of disease progression in patients with advanced hepatocellular carcinoma

Reference for details: Reference fordetails:Reference for details: Reference for details:Reference fordetails:J Gastroenterology H: Levatinib can reduce the risk of disease progression in patients with advanced hepatocellular carcinoma

5.
Br J Cancer: TP53 mutation increases the radiotherapy resistance of rhabdomyosarcoma and Ewing's sarcoma

5.
Br J Cancer：TP535.
Br J Cancer：TP535.
Br J Cancer：TP535.
Br J Cancer：TP53

， (RMS) (ES) ，。（RT），。

， (RMS) (ES) ，。（RT），。， (RMS) (ES) ，。（RT），。， (RMS) (ES) ，。， (RMS) (ES) ，。（RT），。（RT），。

，。RMSES，，。

，。RMSES，，。，。RMSES，，。，。RMSES，，。，。RMSES，，。。

，p53DNA。，RMSESTP53p53。

，p53DNA。，RMSESTP53p53。，p53DNA。，RMSESTP53p53。，p53DNA。，RMSESTP53p53。，p53DNA。，RMSESTP53p53。RMSESTP53p53。RMSESTP53p53。

，TP53RMSES。，p53RMSES。

，TP53RMSES。，p53RMSES。，TP53RMSES。，p53RMSES。，TP53RMSES。，p53RMSES。，TP53RMSES。，p53RMSES。，，TP53RMSES。，p53RMSES。，p53RMSES。

：Br J Cancer：TP53

：：：：：Br J Cancer：TP53

6.
Br J Cancer：

6.
Br J Cancer：6.
Br J Cancer：6.
Br J Cancer：6.
Br J Cancer：

。BC，BCBC。。

1993-2010/。<31≥315（DFS）。5（OS）。

1993-2010/。

，，，≥31DFSOS，，≥315OS。，30。

，≥31DFSOS，，≥315OS。，≥31DFSOS，，≥315OS。

：Br J Cancer：

：：：：：Br J Cancer：

7.
Br J Cancer：II

7.
Br J Cancer：II7.
Br J Cancer：II7.
Br J Cancer：II7.
Br J Cancer：II

(STS) 。，1%。，STS（）。

STS，。，VEGF。VEGF（TKI），（pazopanib）。

，（STS），PFS。，。

，（STS），PFS。，。

、、II（topotecan）STS。，。STS12。

、、II（topotecan）STS。，。STS12。、、II（topotecan）STS。

，，12。。

，，12。。，12。。，12。。

：Br J Cancer：II

：Br J Cancer：II：：：：：Br J Cancer：II

8.
Front Pharmacol：

8.
Front Pharmacol：8.
Front Pharmacol：8.
Front Pharmacol：8.
Front Pharmacol：8.
Front Pharmacol：

（PRAD）。，。，，，。

，，，

，，。，。

Based on the above situation, some researchers have recently constructed a prediction model based on transcriptomics and networks to quickly screen out possible drug combinations for the treatment of prostate cancer, and further evaluate its performance through in vitro experiments .
The researchers screened out nine possible combinations based on transcriptomics methods.
However, the web-based approach gives differences at least for the three drug combinations.

Some researchers have constructed predictive models based on transcriptomics and networks to quickly screen out possible drug combinations for the treatment of prostate cancer, and further evaluate their performance through in vitro experiments

To sum up, for prostate cancer, the method based on transcriptomics is better than the method based on network in terms of predicting the synergistic effect of drug combination, which provides guidance for the selection of calculation method for drug combination screening .
More importantly, they found that six combinations (three mitoxantrone-containing combinations and three cabazitaxel-containing combinations) are promising drug candidates for synergistically combating prostate cancer.

In summary, for prostate cancer, transcriptomics-based methods are better than network-based methods in predicting the synergistic effects of drug combinations, which provides guidance for the selection of calculation methods for drug combination screening

For details, please refer to: Front Pharmacol: A collaborative drug combination study for predicting prostate cancer through transcriptomics and network features

Reference for details: Reference fordetails:Reference fordetails: Reference for details: Reference fordetails:Reference fordetails:Front Pharmacol: Synergistic drug combination study for predicting prostate cancer through transcriptomics and network features

9.
JNNP: Comparison of immune checkpoint inhibitor-related neuropathy in patients with neuroendocrine tumors and non-neuroendocrine tumors

9.
JNNP: Comparison of immune checkpoint inhibitor-related neuropathy in patients with neuroendocrine tumors and non-neuroendocrine tumors 9.
JNNP: Comparison of immune checkpoint inhibitor-related neuropathy in patients with neuroendocrine tumors and non-neuroendocrine tumors 9.
JNNP: Comparison of immune checkpoint inhibitor-related neuropathy inpatients with neuroendocrine tumors and non-neuroendocrine tumors 9.
JNNP:Comparison of immune checkpoint inhibitor-related neuropathy inpatients with neuroendocrine tumors and non-neuroendocrine tumors9.
JNNP: Neuroendocrine tumors and Comparison of immune checkpoint inhibitor-related neuropathy in patients with non-neuroendocrine tumors

The indications for immune checkpoint inhibitors (ICI) have greatly expanded in the past few years.
The purpose of this study is to provide the latest information on the clinical manifestations, serological association and prognosis of ICI-related neuropathy (irNeuropathy) in the cancer immunotherapy of neuroendocrine tumors.
All neuropathy patients evaluated at the Mayo Clinic were identified through an electronic medical record search.
Patients with neuropathy secondary to cytotoxic chemotherapy, radiotherapy, diabetes , structural or compressive causes before taking ICIs were excluded .
Clinical manifestations, diagnostic results, autoantibody profile and clinical results were reviewed.

The indications for immune checkpoint inhibitors (ICI) have greatly expanded in the past few years.
The purpose of this study is to provide the latest information on the clinical manifestations, serological association and prognosis of ICI-related neuropathy (irNeuropathy) in the cancer immunotherapy of neuroendocrine tumors.
All neuropathy patients evaluated at the Mayo Clinic were identified through an electronic medical record search.
Patients with neuropathy secondary to cytotoxic chemotherapy, radiotherapy, diabetes , structural or compressive causes before taking ICIs were excluded .
Clinical manifestations, diagnostic results, autoantibody profile and clinical results were reviewed.
The indications for immune checkpoint inhibitors (ICI) have greatly expanded in the past few years.
The purpose of this study is to provide the latest information on the clinical manifestations, serological association and prognosis of ICI-related neuropathy (irNeuropathy) in the cancer immunotherapy of neuroendocrine tumors.
All neuropathy patients evaluated at the Mayo Clinic were identified through an electronic medical record search.
Patients with neuropathy secondary to cytotoxic chemotherapy, radiotherapy, diabetes , structural or compressive causesbefore taking ICIs were excluded.
Clinical manifestations, diagnostic results, autoantibody profile and clinical results were reviewed.
The indications forimmunecheckpoint inhibitors (ICI) have greatly expanded in the past few years.
The purpose of this study is to provide the latest information on the clinical manifestations, serological association and prognosis of ICI-related neuropathy (irNeuropathy) in the cancer immunotherapy of neuroendocrine tumors.
All neuropathy patients evaluated at the Mayo Clinic were identified through an electronic medical record search.
Patients with neuropathy secondary to cytotoxic chemotherapy, radiotherapy,diabetes, structural or compressive causesbefore taking ICIs were excluded.
Clinical manifestations,diagnosticresults, autoantibody profile and clinical results were reviewed.
immunityThe indications of Immune Immune Checkpoint Inhibitors (ICI) have greatly expanded in the past few years.
The purpose of this study is to provide the latest information on the clinical manifestations, serological association and prognosis of ICI-related neuropathy (irNeuropathy) in the cancer immunotherapy of neuroendocrine tumors.
All neuropathy patients evaluated at the Mayo Clinic were identified through an electronic medical record search.
Patients with neuropathy secondary to cytotoxic chemotherapy, radiotherapy, diabetes , structural or compressive causes before taking ICIs were excluded .
Clinical manifestations, diagnostic results, autoantibody profile and clinical results were reviewed.
The indications for checkpoint inhibitors (ICI) have greatly expanded in the past few years.
The purpose of this study is to provide the latest information on the clinical manifestations, serological association and prognosis of ICI-related neuropathy (irNeuropathy) in the cancer immunotherapy of neuroendocrine tumors.
All neuropathy patients evaluated at the Mayo Clinic were identified through an electronic medical record search.
Patients with neuropathy secondary to cytotoxic chemotherapy, radiotherapy, diabetes , structural or compressive causes before taking ICIs were excluded .
Clinical manifestations, diagnostic results, autoantibody profile and clinical results were reviewed.
Diabetes diagnosis

The research in this article supports that the manifestations and outcomes of neuropathy are changing, as the indications for ICI have been expanded to include tumors typically associated with PNS.
Before the start of ICI, it is important to identify the clinical features of the pre-existing paraneoplastic neuropathy and the evaluation of tumor nerve autoantibodies to avoid the irreversible decline of the neurological function of these patients.

The research in this article supports that the manifestations and outcomes of neuropathy are changing, as the indications for ICI have been expanded to include tumors typically associated with PNS.
Before the start of ICI, it is important to identify the clinical features of the pre-existing paraneoplastic neuropathy and the evaluation of tumor nerve autoantibodies to avoid the irreversible decline of the neurological function of these patients.
The research in this article supports that the manifestations and outcomes of neuropathy are changing, as the indications for ICI have been expanded to include tumors typically associated with PNS.
Before the start of ICI, it is important to identify the clinical features of the pre-existing paraneoplastic neuropathy and the evaluation of tumor nerve autoantibodies to avoid the irreversible decline of the neurological function of these patients.
The research in this article supports that the manifestations and outcomes of neuropathy are changing, as the indications for ICI have been expanded to include tumors typically associated with PNS.
Before the start of ICI, it is important to identify the clinical features of the pre-existing paraneoplastic neuropathy and the evaluation of tumor nerve autoantibodies to avoid the irreversible decline of the neurological function of these patients.
The research in this article supports that the manifestations and outcomes of neuropathy are changing, as the indications for ICI have been expanded to include tumors typically associated with PNS.
Before the start of ICI, it is important to identify the clinical features of the pre-existing paraneoplastic neuropathy and the evaluation of tumor nerve autoantibodies to avoid the irreversible decline of the neurological function of these patients.
The research in this article supports that the manifestations and outcomes of neuropathy are changing, as the indications for ICI have been expanded to include tumors typically associated with PNS.
Before the start of ICI, it is important to identify the clinical features of the pre-existing paraneoplastic neuropathy and the evaluation of tumor nerve autoantibodies to avoid the irreversible decline of the neurological function of these patients.

For details, please refer to: JNNP: Comparison of immune checkpoint inhibitor-related neuropathy in patients with neuroendocrine tumors and non-neuroendocrine tumors

Details Reference: JNNP: neuroendocrine tumors and non-neuroendocrine tumor suppressors Immune checkpoint-related neuropathy patients comparing details reference: JNNP: Comparison of neuroendocrine tumors and non-tumor patients Neuroimmune check point depressants related neuropathydetails reference :JNNP: Comparison of immune checkpoint inhibitor-related neuropathy in patients with neuroendocrine tumors and non-neuroendocrine tumors.
Fordetails, please refer to:JNNP:Comparison of immune checkpoint inhibitor-related neuropathy inpatients with neuroendocrine tumors and non-neuroendocrine tumors.
Fordetails, please refer to:JNNP : Comparison of immune checkpoint inhibitor-related neuropathy in patients with neuroendocrine tumors and non-neuroendocrine tumors.
Fordetails, please refer to: Fordetails: Fordetails, please refer to:JNNP: Comparison of immune checkpoint inhibitor-related neuropathy in patients with neuroendocrine tumors and non-neuroendocrine tumors

10.
Br J Haematol: Targeted capture sequencing for genomic analysis of multiple myeloma

10.
Br J Haematol: Targeted capture sequencing for genomic analysis of multiple myeloma 10.
Br J Haematol: Targeted capture sequencing for genomic analysis of multiple myeloma 10.
Br J Haematol: Targeted capture sequencing for multiple bone marrow Genome analysis oftumors 10.
Br J Haematol: Targeted capture sequencing for genomic analysis of multiple myeloma10.
Br J Haematol: Targeted capture sequencing for genomic analysis of multiple myeloma

Previous genomic studies have revealed the genome map of myeloma cells.
Although some of the displayed genomic abnormalities are thought to be related to the molecular pathogenesis and/or clinical outcome of multiple myeloma, these correlations are not yet fully understood.
The purpose of this study is to clarify the correlation between genomic abnormalities and clinical features in the Japanese multiple myeloma cohort through targeted capture sequencing.

Previous genomic studies have revealed the genome map of myeloma cells.
Although some of the displayed genomic abnormalities are thought to be related to the molecular pathogenesis and/or clinical outcome of multiple myeloma, these correlations are not yet fully understood.
The purpose of this study is to clarify the correlation between genomic abnormalities and clinical features in the Japanese multiple myeloma cohort through targeted capture sequencing.

The researchers analyzed 154 newly diagnosed multiple myeloma patients.
The analysis showed that compared with previous reports, there were fewer hyperdiploid subtypes (37-0%), KRAS mutations (36-4%) and IGH-CCND1 translocations (26-6%) in the cohort of this study.
The frequency is relatively high.
In addition, the targeted capture sequencing strategy can detect rare IGH-related chromosomal translocations, such as IGH-CCND2 and IGH-MAFA.
Interestingly, all 10 patients had MAX mutations with 14q23 deletion.
Patients with del(17p) have poor clinical outcomes, and the presence of KRAS mutations is related to the shorter survival of patients with multiple myeloma carrying IGH-CCND1.

The researchers analyzed 154 newly diagnosed multiple myeloma patients.
The analysis showed that compared with previous reports, there were fewer hyperdiploid subtypes (37-0%), KRAS mutations (36-4%) and IGH-CCND1 translocations (26-6%) in the cohort of this study.
The frequency is relatively high.
In addition, the targeted capture sequencing strategy can detect rare IGH-related chromosomal translocations, such as IGH-CCND2 and IGH-MAFA.
Interestingly, all 10 patients had MAX mutations with 14q23 deletion.
Patients with del(17p) have poor clinical outcomes, and the presence of KRAS mutations is related to the shorter survival of patients with multiple myeloma carrying IGH-CCND1.
The researchers analyzed 154 newly diagnosed multiple myeloma patients.
The analysis showed that compared with previous reports, there were fewer hyperdiploid subtypes (37-0%), KRAS mutations (36-4%) and IGH-CCND1 translocations (26-6%) in the cohort of this study.
The frequency is relatively high.
In addition, the targeted capture sequencing strategy can detect rare IGH-related chromosomal translocations, such as IGH-CCND2 and IGH-MAFA.
Interestingly, all 10 patients had MAX mutations with 14q23 deletion.
Patients with del(17p) have poor clinical outcomes, and the presence of KRAS mutations is related to the shorter survival of patients with multiple myeloma carrying IGH-CCND1.

For details, please refer to: Br J Haematol: Targeted capture sequencing for genomic analysis of multiple myeloma

For details reference: Br J Haematol: Targeted capture sequencing for genomic analysis of multiple myeloma.
For more details: Br J Haematol: Targeted capture sequencing for genomic analysis of multiple myeloma.
Fordetails:Reference fordetails: Fordetails:Reference fordetails:details reference:Br J Haematol: capture targeted sequencing of genomic analysis of multiple myeloma

in this message